Sab Biotherapeutics Inc (SABS) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Sab Biotherapeutics Inc   (NASDAQ: SABS)


Sab Biotherapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Sab Biotherapeutics Inc's ROI in the second quarter of 2026?
Sab Biotherapeutics Inc recorded a cumulative net loss of $-13 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -6.39%.

Within the Healthcare sector 224 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2201 to 2555.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 519.53 % 261.49 % 92.7 % 9.03 % -38.42 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 227 239 162 173 19
Return On Investment (TTM) -6.39 % -0.27 % 13.87 % 29.19 % -114.8 %
SABS's Overall Ranking # 2555 # 2201 # 418 # 196 # 3000
Seq. Investment Change TTM 34.92 % 54.91 % 49.03 % 98.88 % -21.27 %
Seq. Net Income Change TTM - - -29.17 % - -
Net Income (TTM) in Millions -13 0 13 19 -37

SABS Company Profile >> Back to SABS Roi Comparisons >> See Annual SABS Return On Investment



Return On Investment SABS's Ranking
Within: No.
Industry # 22
Sector # 225
Overall # 2555

Return On Investment Statistics
High Average Low
29.19 %
-48.64 %
-115.84 %
(Sep 30 2025)   (Dec 31 2023)







Financial Statements
Sab Biotherapeutics Inc's II. Quarter Investments $ 227 Millions SABS's Balance sheet
Sab Biotherapeutics Inc's II. Quarter Income $ -22 Millions Quarterly SABS's Income Statement
SABS's Income by Division See SABS's Income by Division


SABS Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 162 36 73 36 55
Y / Y Investment Growth 347.67 % -50.48 % 103.63 % -34.33 % 31.32 %
Net Income in Millions 13 -34 -42 -19 -17
Y / Y Net Income Growth - - - - -
Annual Return On Investment 8.19 % -94.17 % -57.7 % -52.19 % -31.35 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 8.19 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
SABS's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for SABS's Competitors
Subscribers only: Roi for Sab Biotherapeutics Inc's Suppliers
Subscribers only: Return On Investment for SABS's Customers

Other Ratios
SABS's Roa SABS's Inventory Turnover Ratio SABS's Growth Rates SABS's Dividend Statistics
SABS's Profitability Ratios SABS's Asset Turnover Ratio SABS's Dividend Growth
SABS's Roe SABS's Valuation Ratios SABS's Financial Strength Ratios SABS's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-26T07:39:49+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.